Abstract

Spatial transcriptomics (ST) technology through in situ capturing has enabled topographical gene expression profiling of tumor tissues. However, each capturing spot may contain diverse immune and malignant cells, with different cell densities across tissue regions. Cell type deconvolution in tumor ST data remains challenging for existing methods designed to decompose general ST or bulk tumor data. We develop the Spatial Cellular Estimator for Tumors (SpaCET) to infer cell identities from tumor ST data. SpaCET first estimates cancer cell abundance by integrating a gene pattern dictionary of copy number alterations and expression changes in common malignancies. A constrained regression model then calibrates local cell densities and determines immune and stromal cell lineage fractions. SpaCET provides higher accuracy than existing methods based on simulation and real ST data with matched double-blind histopathology annotations as ground truth. Further, coupling cell fractions with ligand-receptor coexpression analysis, SpaCET reveals how intercellular interactions at the tumor-immune interface promote cancer progression.

Cell type deconvolution in tumor spatial transcriptomics (ST) data remains challenging. Here, the authors develop Spatial Cellular Estimator for Tumors (SpaCET) to infer cell types and intercellular interactions from ST data in cancer across different platforms, with improved performance over similar methods.

Details

Title
Estimation of cell lineages in tumors from spatial transcriptomics data
Author
Ru, Beibei 1   VIAFID ORCID Logo  ; Huang, Jinlin 2 ; Zhang, Yu 3 ; Aldape, Kenneth 4   VIAFID ORCID Logo  ; Jiang, Peng 1   VIAFID ORCID Logo 

 National Institutes of Health, Cancer Data Science Lab, Center for Cancer Research, National Cancer Institute, Bethesda, USA (GRID:grid.94365.3d) (ISNI:0000 0001 2297 5165) 
 The University of Hong Kong, Department of Clinical Oncology, Li Ka Shing Faculty of Medicine, Hong Kong, China (GRID:grid.194645.b) (ISNI:0000000121742757); Sun Yat-sen University Cancer Center, Guangzhou, Department of Pathology, Guangdong, China (GRID:grid.488530.2) (ISNI:0000 0004 1803 6191) 
 National Institutes of Health, Cancer Data Science Lab, Center for Cancer Research, National Cancer Institute, Bethesda, USA (GRID:grid.94365.3d) (ISNI:0000 0001 2297 5165); The University of Hong Kong, Department of Clinical Oncology, Li Ka Shing Faculty of Medicine, Hong Kong, China (GRID:grid.194645.b) (ISNI:0000000121742757); Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangzhou, China (GRID:grid.488530.2) (ISNI:0000 0004 1803 6191) 
 National Institutes of Health, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, USA (GRID:grid.94365.3d) (ISNI:0000 0001 2297 5165) 
Pages
568
Publication year
2023
Publication date
2023
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2771822611
Copyright
© This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.